Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment

Oman Medical Journal

Rosline Hassan¹  Hafizuddin Mohamed Fauzi²  Noor Haslina Mohd Noor²  Mohd Nazri Hassan³  Mohd Ismail Ibrahim³  Rapiaah Mustaffa⁴  Azlan Husin⁵ 

[1] Department of Medicine, School of Medical Sciences, Health Campus, Universiti Sains Malaysia,Kelantan, Malaysia;Health Campus, Hospital Universiti Sains Malaysia, Kelantan, Malaysia;Department of Hematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kelantan, Malaysia;Health Campus, Hospital Universiti Sains Malaysia, Kelantan, Malaysia;Regenerative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia,Bertam, Pulau Pinang, Malaysia;

关键词: Autologous Transplantation;    Multiple Myeloma;    Lymphoma;    Lymphoproliferative Disorder;    Stem Cell;   

DOI  :  10.5001/omj.2019.06

来源: DOAJ

【 摘 要 】

Objectives: Autologous peripheral blood stem cells transplantation (APBSCT) is a therapeutic option which can be used in various hematological, neoplastic disorders including lymphoproliferative disease (LPD). Differences in patient populations and treatment modalities in different transplant centers mean it is important to improve the knowledge of the different factors affecting engraftment after APBSCT for the success of this procedure. We sought to determine the factors influencing neutrophil and platelet engraftment after APBSCT in patients with LPD. Methods: We conducted a retrospective review of 70 patients with LPD (35 with lymphoma and 35 with multiple myeloma) who had undergone APBSCT between January 2008 and December 2016. Data obtained included disease type, treatment, and stem cell characteristics. Kaplan-Meier analysis was performed for probabilities of neutrophil and platelet engraftment occurred and was compared by the log-rank test. The multivariate Cox proportional hazards regression model was used for the analysis of potential independent factors influencing engraftment. A p-value < 0.050 was considered statistically significant. Results: Most patients were ethnic Malay, the median age at transplantation was 49.5 years. Neutrophil and platelet engraftment occurred in a median time of 18 (range 4–65) and 17 (range 6–66) days, respectively. The majority of patients showed engraftment with 65 (92.9%) and 63 (90.0%) showing neutrophil and platelet engraftment, respectively. We observed significant differences between neutrophil engraftment and patient’s weight (< 60/≥ 60 kg), stage of disease at diagnosis, number of previous chemotherapy cycles (< 8/≥ 8), and pre-transplant radiotherapy. While for platelet engraftment, we found significant differences with gender, patient’s weight (< 60/≥ 60 kg), pre-transplant radiotherapy, and CD34+ dosage (< 5.0/≥ 5.0 × 106/kg and < 7.0/≥ 7.0 × 106/kg). The stage of disease at diagnosis (p = 0.012) and pre-transplant radiotherapy (p = 0.025) were found to be independent factors for neutrophil engraftment whereas patient’s weight (< 60/≥ 60 kg, p = 0.017), age at transplantation (< 50/≥ 50 years, p = 0.038), and CD34+ dosage (< 7.0/≥ 7.0 × 106/kg, p = 0.002) were found to be independent factors for platelet engraftment. Conclusions: Patients with LPD who presented at an early stage and with no history of radiotherapy had faster neutrophil engraftment after APBSCT, while a younger age at transplantation with a higher dose of CD34+ cells may predict faster platelet engraftment. However, additional studies are necessary for better understanding of engraftment kinetics to improve the success of APBSCT.

【 授权许可】

Unknown